Serum YKL-40 Level Is Associated with the Chemotherapy Response and Prognosis of Patients with Small Cell Lung Cancer

Xu, Chunhua; Liu, Yu; Hao, Ke-Ke

doi:10.1371/journal.pone.0096384

Cited by 21 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, it was shown that YKL-40 is a potential prognostic marker of chemotherapy response in SCLC. Serum levels of YKL-40 were significantly correlated with disease stage, while there were no difference with age, gender, smoking status and performance status in this study (24).…”

Section: Discussioncontrasting

confidence: 58%

The place of ykl-40 in non-small cell lung cancer

Gunes¹,

Gul

Tutar³

et al. 2014

Tuberk Toraks

View full text Add to dashboard Cite

The place of YKL-40 in non-small cell lung cancer Introduction: Despite varies treatment options, the survival rate of non-small cell lung cancer (NSCLC) is less than 1%. If biological behaviour of any cancer could be known, the information would potentially tailor the clinical work-up, assesment and treatment. The prognostic value of serum YKL-40 level has been investigated in different types of cancer and showed poor prognostic indication with more aggressive clinical course. We studied the role of serum YKL-40 levels in patients with NSCLC to determine the stage. Materials and Methods: Serum YKL-40 levels in venous blood samples of 55 patients was studied. 49 (89.1%) male and 6 (10.9%) female newly diagnosed NSCLC patients whom received neither cancer specific or symptom relieving treatment are enrolled. TNM staging was determined based on the findings of computerized tomography (CT), positron emission tomography (PET), cranial magnetic resonance imaging (MRI), bronchoscopy and mediastinoscopy. The patients with NSCLC were divided into two groups; Group A: stage Ia, Ib, IIa, IIb, Group B: stage IIIa, IIIb and IV. Results: There was a statistical difference in YKL-40 serum levels between groups (Group A, Group B) when compared (p< 0.05). A medium and statistical correlation was found (r= 0.48; p< 0.01) between YKL-40 levels and age. Conclusion: YKL-40 levels in advanced stage NSCLC (stage III, IV) was found to be significantly high compared to early stage. It should be kept in mind that when YKL levels are high, higher stages of the disease should be suspected and future tests should be performed.

show abstract

Section: Discussioncontrasting

confidence: 58%

The place of ykl-40 in non-small cell lung cancer

Gunes¹,

Gul

Tutar³

et al. 2014

Tuberk Toraks

View full text Add to dashboard Cite

show abstract

“…High CHI3L1 expression was independently associated with poorer overall survival in both NSCLC and SCLC patients (103). Serum CHI3L1 levels in 120 SCLC patients were higher in the group with a poorer response to chemotherapy and those revealing a shorter survival (104).…”

Section: Chi3l1 In Inflammation and Cancermentioning

confidence: 94%

Circulating tumor cell interactions with macrophages: implications for biology and treatment

Hamilton¹,

Rath²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

CTCs. SCLC has an unfavorable prognosis due to rapid dissemination and early chemoresistant relapses. SCLC CTCs recruit macrophages and elicit secretion of various cytokines and the six CTC lines expresschitinase-3-like-1 (CHI3L1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP9) in abundance. CHI3L1 is cytokine/growth factor expressed in inflammation and cancer and found to be correlated to metastasis and a dismal prognosis. In conclusion, SCLC CTCs have acquired the essential means for aggressiveness and invasion in a tumor microenvironment specifically shaped by macrophages and inflammation.

show abstract

“…Therefore, the 5‐year survival rate of SCLC is still very low . Progastrin‐releasing peptide (ProGRP), YKL‐40 and neuron‐specific enolase (NSE) is commonly used tumor markers for tumor diagnosis . However, these widely used serum marker are not sufficiently accurate to be useful as a diagnostic test.…”

Section: Introductionmentioning

confidence: 99%

Serum pleiotrophin as a diagnostic and prognostic marker for small cell lung cancer

Wang

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Pleiotrophin (PTN) is involved in tumour progression, angiogenesis and metastasis. The purpose of this study was to investigate the expression level of PTN in the serum of patients with small cell lung cancer (SCLC) and to explore the clinical significance of PTN. Serum samples from 128 patients with SCLC, 120 healthy volunteers (HV) and 60 patients with benign lung disease (BLD) were collected. The levels of serum PTN were determined with ELISA and its correlation with the clinical data was examined. The serum PTN levels in SCLC patients were significantly higher than that in BLD patients ( P < 0.05) or HV ( P < 0.05). With a cutoff value of 258.18 ng/mL, the sensitivity and specificity of PTN to SCLC patients and BLD patients, SCLC patients and HV were 79.2% and 91.7%, 86.7% and 95.8% respectively. An area under the curve for all stages of SCLC resulting from PTN, which was significantly better than the other tumour markers tested including progastrin‐releasing peptide and neuron‐specific enolase. High serum PTN levels appear to correlate with poor survival in patients with SCLC. These results suggest that PTN levels in the serum could be a new effective biomarker for the diagnosis and prognosis of SCLC.

show abstract

Serum YKL-40 Level Is Associated with the Chemotherapy Response and Prognosis of Patients with Small Cell Lung Cancer

Cited by 21 publications

References 29 publications

The place of ykl-40 in non-small cell lung cancer

The place of ykl-40 in non-small cell lung cancer

Circulating tumor cell interactions with macrophages: implications for biology and treatment

Serum pleiotrophin as a diagnostic and prognostic marker for small cell lung cancer

Contact Info

Product

Resources

About